Versartis Inc. (NASDAQ:VSAR)’s share price rose 2% during trading on Thursday . The stock traded as high as $12.83 and last traded at $12.65, with a volume of 107,392 shares changing hands. The stock had previously closed at $12.40.

VSAR has been the topic of several research analyst reports. Canaccord Genuity restated a “buy” rating on shares of Versartis in a report on Tuesday, May 10th. Zacks Investment Research cut shares of Versartis from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Citigroup Inc. set a $23.00 price target on shares of Versartis and gave the company a “buy” rating in a report on Thursday, August 11th. Finally, Credit Suisse Group AG restated a “sell” rating and set a $9.00 price target on shares of Versartis in a report on Friday, July 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $18.00.

The firm’s market capitalization is $388.46 million. The stock has a 50 day moving average price of $11.88 and a 200 day moving average price of $9.61.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.03. On average, equities analysts anticipate that Versartis Inc. will post ($2.76) EPS for the current fiscal year.

In related news, CEO Jay Shepard sold 5,442 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $12.88, for a total value of $70,092.96. Following the transaction, the chief executive officer now directly owns 155,358 shares in the company, valued at $2,001,011.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.